Carrier advocacy coverage letter for Yttrium-90 (Y-90) transarterial radioembolization (TARE)
This product is provided in a downloadable PDF format.
The Yttrium-90 (Y-90) transarterial radioembolization (TARE) evidence based letter was written by IR Physicians who are members of SIR's carrier advocacy workgroup. The letter is intended to help IR's during the authorization, appeal and denial process with any payor denying this service.
Policy coverage topic: Yttrium-90 (Y-90) transarterial radioembolization (TARE) as a treatment for hepatocellular carcinoma (HCC)
A subscription model applies to this product. The text, graphics, and information are of general nature; it is not a substitute for obtaining medical advice. We may update the documents at any time without prior notice.
A patient appeal letter is available for this procedure. These patient-facing resources are designed to help individuals whose insurance coverage has been denied explain the medical necessity of the recommended treatment and formally request reconsideration from their payer.
Physicians may choose to share this letter with their patients to support the appeals process.